The biotechnology industry is getting more attention than usual following a buyout offer for Alpine Immune Sciences (NASDAQ: ALPN) from Vertex Pharmaceuticals (NASDAQ: VRTX).

Vertex recently offered Alpine Immune Sciences $65 per share, or about $4.9 billion in cash. On April 9, the day before the announcement, Alpine's stock price closed at about $39 per share.

Government regulators rarely try to prevent big pharmaceutical companies from acquiring clinical-stage biotechs. This means Alpine shareholders will most likely see their investment increase by about 67% when the deal closes, probably in a couple of months.

Continue reading

Source Fool.com